Company intelligence
Flare Therapeutics
Trailblazing the path to drugging transcription factors to discover precision medicines for cancer & other disease areas
About Flare Therapeutics
Our team is developing precision medicines for oncology and other therapeutic areas. We are exclusively focused on drugging transcription factors to fully unlock the therapeutic potential of this previously elusive target class. By leveraging our integrated discovery platform of capabilities, we identify novel validated ligands to the undrugged proteome. Our lead program, FX-909, is a first-in-class orally available small molecule inhibitor of PPARG, a master regulator of the luminal lineage, that is initially being developed for locally advanced or metastatic urothelial cancer. FX-909 has achieved clinical proof-of-concept in a Phase 1A study as a monotherapy and is actively dosing patients in a Phase 1B. Our second lead program, FX-111, is a novel and highly differentiated potent and selective degrader for ARON, the transcriptionally active, hormone-bound androgen receptor.
Verified activity
Signals from Flare Therapeutics
4 published signals
People
Flare Therapeutics welcomed Peter Lebowitz, MD, PhD, to its Board of Directors.
Reported by Flare Therapeutics
People
Flare Therapeutics appointed Brian DeSchuytner as Chief Financial Officer and Chief Business Officer.
Reported by Flare Therapeutics
Strategy & Corporate Development
Flare Therapeutics appointed Peter as a member of the board of FlareTx to provide input into the advancement of AR(ON) FX111 and AR(ON)-RIPTAC, two potentially transformational therapies for prostate cancer.
Reported by Anna Protopapas
Research & Knowledge
Flare Therapeutics published its work on Y220C demonstrating that the mutation compromises zinc binding through the peer review process.
Reported by Jacob Stuckey, PhD